## Introduction And The aim of work

## INTRODUCTION

Schistosomiasis is a chronic and debilitating disease that exacerbates poverty (King, 2007). Although close to 800 million individuals are at risk of contracting the disease and over 200 million people are thought to be infected, schistosomiasis is often neglected (Hotez et al., 2009).

Morbidity due to schistosomiasis includes hepatic and intestinal fibrosis (S. mansoni and S. japonicum), and ureteric and bladder fibrosis and calcification of the genitourinary tract (S. haematobium) (Gryseels et al., 2006).

In schistosomiasis, there is yet no vaccine available and the current mainstay of control is chemotherapy. Praziquantel(PZQ) is the drug of choice for the treatment of schistosomiasis (Utzinger et al., 2001), because of its safety, broad-spectrum activity, and reasonable cost(Cioli, 2000).

In view of concern about the development of tolerance or resistance (or both) to PZQ and because of the efficacy of PZQ against adult worms only, there is a need for the development of new drugs for the treatment of schistosomiasis, a number of compounds with promising antischistosomal properties have been identified (Xiao et al., 2007), the cysteine protease inhibitors and K11777alkylaminoalkanethiosulfuric acids (Abdulla et al., 2007).

In such areas, it might be possible the use of mefloquine which is antimalarial drug (White, 2008) also as antischistosomal drug (Xio et al., 2002). The antimalarials artemether and mefloquine have promising antischistosomal properties (Keiser and Utzinger, 2007).

However, the mechanisms of action of these schistosomicides are not yet known. Mefloquine might inhibit hemozoin formation (*Keiser et al.*, 2009) and it has been shown that artemether interacts with haemin to

exert a toxic effect on schistosomes (Xiao et al., 2001). Interestingly, artemether also exhibits immunosuppressive activity (Wang et al., 2009).

Oral administration of a single dose of mefloquine (400mg/kg) to mice infected with either juvenile or adult stages of *S. mansoni* and *S. japonicum*, two of the three most important schistosome species resulted in very high or complete total and female worm burden reductions (*Gryseels et al.*, 2006).